CI
VRTX icon

Conning Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Conning Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$521K Sell
1,167
-233
-17% -$109K 0.02% 205
2025
Q4 		$635K Sell
1,400
-144
-9% -$62.1K 0.02% 209
2025
Q3 		$605K Hold
1,544
– – 0.02% 214
2025
Q2 		$687K Sell
1,544
-42
-3% -$19.4K 0.02% 199
2025
Q1 		$769K Buy
1,586
+172
+12% +$80.2K 0.03% 194
2024
Q4 		$569K Sell
1,414
-89
-6% -$41.3K 0.02% 208
2024
Q3 		$699K Sell
1,503
-18
-1% -$8.65K 0.02% 201
2024
Q2 		$713K Buy
1,521
+33
+2% +$14.3K 0.03% 194
2024
Q1 		$622K Sell
1,488
-40
-3% -$16.9K 0.02% 207
2023
Q4 		$622K Buy
1,528
+10
+0.7% +$3.69K 0.02% 200
2023
Q3 		$528K Sell
1,518
-20
-1% -$7K 0.02% 206
2023
Q2 		$541K Sell
1,538
-235
-13% -$79.2K 0.02% 211
2023
Q1 		$559K Sell
1,773
-20
-1% -$6K 0.02% 218
2022
Q4 		$518K Sell
1,793
-8
-0.4% -$2.44K 0.02% 234
2022
Q3 		$521K Sell
1,801
-102
-5% -$29.3K 0.02% 221
2022
Q2 		$536K Sell
1,903
-22
-1% -$5.89K 0.02% 238
2022
Q1 		$502K Sell
1,925
-170
-8% -$40.3K 0.01% 259
2021
Q4 		$460K Sell
2,095
-399
-16% -$77.6K 0.01% 271
2021
Q3 		$452K Sell
2,494
-590
-19% -$115K 0.01% 284
2021
Q2 		$622K Sell
3,084
-303
-9% -$63.4K 0.02% 247
2021
Q1 		$728K Sell
3,387
-300
-8% -$65.9K 0.02% 225
2020
Q4 		$871K Sell
3,687
-15
-0.4% -$3.44K 0.03% 213
2020
Q3 		$1.01M Buy
3,702
+69
+2% +$19K 0.04% 183
2020
Q2 		$1.05M Sell
3,633
-254
-7% -$68.9K 0.04% 172
2020
Q1 		$925K Buy
3,887
+7
+0.2% +$1.61K 0.04% 182
2019
Q4 		$850K Buy
3,880
+40
+1% +$8.1K 0.03% 223
2019
Q3 		$651K Hold
3,840
– – 0.02% 280
2019
Q2 		$704K Sell
3,840
-1,559
-29% -$273K 0.02% 256
2019
Q1 		$993K Sell
5,399
-60
-1% -$11.1K 0.03% 249
2018
Q4 		$905K Sell
5,459
-490
-8% -$84.9K 0.03% 242
2018
Q3 		$1.15M Sell
5,949
-180
-3% -$32.1K 0.03% 251
2018
Q2 		$1.04M Sell
6,129
-90
-1% -$14K 0.03% 277
2018
Q1 		$1.01M Sell
6,219
-110
-2% -$18K 0.03% 267
2017
Q4 		$948K Sell
6,329
-70
-1% -$10.4K 0.03% 286
2017
Q3 		$973K Sell
6,399
-90
-1% -$13.5K 0.03% 274
2017
Q2 		$836K Buy
6,489
+390
+6% +$46.9K 0.03% 313
2017
Q1 		$667K Sell
6,099
-140
-2% -$12.3K 0.02% 339
2016
Q4 		$460K Buy
6,239
+439
+8% +$35.7K 0.02% 406
2016
Q3 		$506K Buy
5,800
+60
+1% +$5.67K 0.02% 388
2016
Q2 		$494K Buy
5,740
+20
+0.3% +$1.73K 0.02% 379
2016
Q1 		$455K Buy
5,720
+110
+2% +$9.95K 0.02% 381
2015
Q4 		$706K Sell
5,610
-320
-5% -$38.6K 0.03% 308
2015
Q3 		$618K Sell
5,930
-580
-9% -$74.5K 0.03% 311
2015
Q2 		$804K Sell
6,510
-50
-0.8% -$6.3K 0.03% 300
2015
Q1 		$774K Buy
6,560
+90
+1% +$10.8K 0.03% 295
2014
Q4 		$769K Sell
6,470
-140
-2% -$15.8K 0.04% 293
2014
Q3 		$742K Buy
6,610
+840
+15% +$80K 0.04% 293
2014
Q2 		$546K Buy
5,770
+490
+9% +$34.4K 0.03% 349
2014
Q1 		$373K Buy
+5,280
New +$418K 0.02% 430

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Conning Inc's VRTX Position: Q1 2026 in Review

Conning Inc reduced its Vertex Pharmaceuticals (VRTX) stake by 17% in Q1 2026, selling an estimated $109K and leaving 1,167 shares worth $521K. The position accounts for 0.02% of the portfolio, ranked #205.

Conning Inc first reported a position in VRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $1.15M in Q3 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Conning Inc held 1,167 shares of Vertex Pharmaceuticals worth $521K as of Q1 2026.
  • Conning Inc sold 233 Vertex Pharmaceuticals shares in Q1 2026, an estimated $109K.
  • Vertex Pharmaceuticals made up 0.02% of Conning Inc's portfolio in Q1 2026, its #205 holding.
  • Conning Inc first reported a position in Vertex Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
  • Conning Inc's Vertex Pharmaceuticals position peaked at $1.15M in Q3 2018.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Conning Inc's 13F filing for Q1 2026, filed 30 Apr 2026.